La inmunizaciónha sido probada en animales con resultados positivos
Un proyecto de investigación impulsado por la Generalitat, el Institut de Recerca de la Sida (IrsiCaixa) y el Hospital Clínic ha identificado un candidato a vacuna contra el VIH, según anunció ayer en Barcelona el doctor Bonaventura Clotet, director del centro de investigación IrsiCaixa y codirector del proyecto junto al doctor Josep Maria Gatell.Clotet calificó ayer de "gran avance" los resultados del Proyecto de Investigación de la Vacuna del Sida (Hivacat), iniciado hace cinco años. "Se ha hecho mucho en poco tiempo, pero no se puede ir más rápido", porque, afirmó, no se podrán ver resultados definitivos antes de dos años. Clotet explicó que Barcelona acogerá en 2013 el congreso internacional de vacunas contra el VIH. Esta es la tercera vacuna que Hivacat está probando.
Barcelona acogerá en 2013 el congreso de vacunas contra el VIH
El coordinador científico Christian Brander apuntó que falta un largo proceso hasta que se pueda probar la vacuna en el primer grupo de unas 20 personas, a pesar de los resultados satisfactorios en los ensa-yos con animales. Un fragmento de la proteína gp41 de la membrana del VIH podría ser la clave. Los investigadores han identificado ese fragmento, que quedaba "escondido" debajo de otros evitando así las defensas inmunitarias y que, una vez expuesto por medio de una vacuna, puede ser un buen estímulo del sistema inmunológico. En la sesión informativa estuvo presente la premio Nobel de Medicina 2008 por el descubrimiento del virus del sida, Françoise Barre-Sinousi, quien subrayó que estamos cambiando "nuestra manera de pensar y trabajando a la vez en vacunas terapéuticas y profilácticas".
Julià Blanco, del IrsiCaixa, explicó que trabajan con métodos para destruir las células infectadas y evitar que se repliquen, además de con anticuerpos neutralizantes. Blanco explicó que la dificultad de crear la vacuna se encuentra en el hecho de que la variabilidad del VIH en una sola persona es superior a la del virus de la gripe en toda una infección global.
Fuente: Público.es
The inmunizaciónha been tested in animals with positive results
A research project promoted by the Generalitat, the Institute for Research in AIDS (IrsiCaixa) and the Hospital Clinic has identified a candidate HIV vaccine, announced yesterday in Barcelona Dr. Bonaventura Clotet, director of the research center and IrsiCaixa project co-director with Dr. Josep Maria Gatell.
Clotet yesterday called "breakthrough" results of the Research Project of the AIDS Vaccine (HIVACAT), launched five years ago. "There has been much too soon, but you can not go faster" because, he said, no final results can be seen within two years. Clotet explained that Barcelona will host in 2013 the international conference on HIV vaccines. This is the third HIVACAT vaccine being tested.
Barcelona will host in 2013 the congress of HIV vaccines
The scientific coordinator Christian Brander said that there is a long process until you can test the vaccine in the first group of 20 people, despite the satisfactory results in animal assays. A fragment of the membrane protein gp41 of HIV could be the key. Researchers have identified this fragment, which was "hidden" under other thus preventing the immune system and, once exposed by a vaccine, can be a good stimulation of the immune system.
At the briefing attended the 2008 Nobel Prize in Medicine for discovering the AIDS virus, Françoise Barre-Sinousi, who stressed that we are changing "our way of thinking and working simultaneously in prophylactic and therapeutic vaccines."
Julià Blanco, IrsiCaixa said working with methods to destroy infected cells and prevent them from replicating, in addition to neutralizing antibodies. White explained that the difficulty of creating the vaccine is in the fact that the variability of HIV in one person is superior to influenza virus infection throughout a global
A research project promoted by the Generalitat, the Institute for Research in AIDS (IrsiCaixa) and the Hospital Clinic has identified a candidate HIV vaccine, announced yesterday in Barcelona Dr. Bonaventura Clotet, director of the research center and IrsiCaixa project co-director with Dr. Josep Maria Gatell.
Clotet yesterday called "breakthrough" results of the Research Project of the AIDS Vaccine (HIVACAT), launched five years ago. "There has been much too soon, but you can not go faster" because, he said, no final results can be seen within two years. Clotet explained that Barcelona will host in 2013 the international conference on HIV vaccines. This is the third HIVACAT vaccine being tested.
Barcelona will host in 2013 the congress of HIV vaccines
The scientific coordinator Christian Brander said that there is a long process until you can test the vaccine in the first group of 20 people, despite the satisfactory results in animal assays. A fragment of the membrane protein gp41 of HIV could be the key. Researchers have identified this fragment, which was "hidden" under other thus preventing the immune system and, once exposed by a vaccine, can be a good stimulation of the immune system.
At the briefing attended the 2008 Nobel Prize in Medicine for discovering the AIDS virus, Françoise Barre-Sinousi, who stressed that we are changing "our way of thinking and working simultaneously in prophylactic and therapeutic vaccines."
Julià Blanco, IrsiCaixa said working with methods to destroy infected cells and prevent them from replicating, in addition to neutralizing antibodies. White explained that the difficulty of creating the vaccine is in the fact that the variability of HIV in one person is superior to influenza virus infection throughout a global
No hay comentarios:
Publicar un comentario